Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2020 Net Income-$681.15K-$681.15KderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$596,324N/M Operating Cash Flowderived-$581,819N/M ended Aug 31, 2021 · filed Nov 29, 2021 · 90 d after period end